Hiroshi Wakabayashi

Department of Nuclear Medicine, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan

[ 1 ] - Feasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol

Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand...

[ 2 ] - Utility of 123I-MIBG Standardized Uptake Value in Patients with Refractory Pheochromocytoma and Paraganglioma

Objective(s): Single-photon emission computed tomography (SPECT) using metaiodobenzylguanidine (MIBG) is an important diagnostic tool for the treatment of refractory pheochromocytoma and paraganglioma (PPGL). Owing to the difficulty of SPECT quantification, the tumour-to-background ratio (TBR) is used to assess disease activity. However, the utility of TBR is limited o...

Co-Authors

Anri Inaki 2  

Seigo Kinuya 2  

Kenichi Yoshimura 1  

Raita Araki 1  

Ryosei Nishimura 1  

Toshinori Murayama 1  

Yasuhito Imai 1  

Yoshikazu Kuribayashi 1  

Daiki Kayano 1  

Hiroshi Mori 1  

Hiroto Yoneyama 1  

Norihito Akatani 1  

Satoru Watanabe 1  

Takafumi Yamase 1  

Takahiro Konishi 1  

Tomo Hiromasa 1